SCHEMBL211788

SCHEMBL211788

OCC(O)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNA5 P22460 7/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
SCN5A Q14524 1/20 0.46
KCND3 Q9UK17 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
KCNH2 Q12809 1/20 0.43
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 1/20 0.42
IDO1 P14902 1/20 0.41
KCNE1 P15382 2/20 0.41
MAPT P10636 1/20 0.41
CYP2D6 P10635 2/20 0.41
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481541 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL30663811 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL1856673 0.85 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL7306898 0.85 KDM4E (0.49) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL30910020 0.84 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL31744336 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL506917 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL7268370 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL29767197 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL6575099 0.82 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2025-07-17 US disclosed
US-20240294512-A1 HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-09-05 US disclosed
EP-3388486-B1 A CROSSLINKABLE COMPOSITION AND METHOD OF PRODUCING THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2021-06-02 EP disclosed
US-8993773-B2 Process to prepare pioglitazone via several novel intermediates CADILA HEALTHCARE LIMITED (IN) 2015-03-31 US disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-20140088127-A1 NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES CADILA HEALTHCARE LIMITED (IN) 2014-03-27 US disclosed
US-8445685-B2 Process to prepare pioglitazone via several novel intermediates CADILA HEALTHCARE LIMITED (IN) 2013-05-21 US disclosed
US-8173816-B2 Process to prepare pioglitazone via several novel intermediates CADILA HEALTHCARE LIMITED (IN) 2012-05-08 US disclosed
US-20120077848-A1 NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES CADILA HEALTHCARE LIMITED (IN) 2012-03-29 US disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
EP-1406605-A1 CARBAMATES OF 2-HETEROCYCLIC-1,2-ETHANEDIOLS SK Corporation (KR) 2004-04-14 EP disclosed
US-20030078235-A1 Carbamates of 2-heterocyclic-1,2-ethanediols SK BIOPHARMACEUTICALS CO., LTD. (KR) 2003-04-24 US disclosed
US-6506943-B1 Reacting 1,2-diol with oxygen in presence of organic ruthenium complex as catalytic component supported on carrier to oxidatively cleave bond between two carbon atoms bearing hydroxyl groups and yield corresponding aldehyde DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-14 US disclosed
WO-2003000247-A1 CARBAMATES OF 2-HETEROCYCLIC-1,2-ETHANEDIOLS SK CORPORATION (KR) 2003-01-03 WO disclosed
CN-1296468-A method for producing aldehyde DAICEL CHEMICA IND LTD (JP) 2001-05-23 CN disclosed
EP-1078907-A1 PROCESS FOR PRODUCING ALDEHYDES Daicel Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
EP-0578194-B1 Process for producing phenol and methyl ethyl ketone SUMITOMO CHEMICAL CO (JP) 1998-02-04 EP disclosed
US-5304684-A Oxidizing sec-butylbenzene to hydroperoxide, concentrating, decomposing, neutralizing, distilling, washing SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1994-04-19 US disclosed
EP-0578194-A2 Process for producing phenol and methyl ethyl ketone SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1994-01-12 EP disclosed
US-4111917-A POLYURETHANES W. R. GRACE & CO. (US) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294512-A1 HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS TRPV1, NHERF1, HCN4 SLC6A2 182/4885SLC6A4 178/4885SLC6A3 259/4885
US-20140088127-A1 NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES PPARD, PPARG, PPARA SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885
US-20120077848-A1 NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES PPARD, PPARG, PPARA SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME UPF1, NUDT21, RNGTT SLC6A2 2609/4885SLC6A4 1941/4885SLC6A3 2073/4885
US-20030078235-A1 Carbamates of 2-heterocyclic-1,2-ethanediols CNR2, CNR1, GRIN2C SLC6A2 1992/4885SLC6A4 2797/4885SLC6A3 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.